Genmab — November 2017
-
TheNote - den absolut største bekymring pt med hensyn til CAR-T er bivirkningsprofilen. Der ses CRS hos mange af patienterne og det kan være fatalt. Herefter er den næststørste bekymring at det kræver special laboratorium og personale og herefter pris. Så der er en del ting som skal fikses før det for alvor bliver en konkurrent, men det arbejdes der selvfølgelig på.
-
Ny hæder til Florian. http://medwatch.dk/secure/Medicinal___Biotek/article9993109.ece
-
who could make a comm
ent on the smoldering abstract? ( centaurus, #510, https://ash.confex.com/ash/2017/webprogram/Paper106028.html ) -
Jeg er enig med TheNote i at en behandling med CAR-T er meget billigere end 5 års dara/rev/dex. Så prismæssigt har CAR-T er Formel!
-
Bivirkninger p.t. givetvis til fordel for dara/rev/dex eller dara/pom/dex
-
fordel
-
agee EL
-
Speaking of CAR-T. Juno was up 7.5% yesterday. Is now up 140% YTD. Someone is beliebig in this CAR-T stuff. They certainly must all be some blind retail shareholders being fuelled by the big Boys

-
believing - fooled
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind